Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a research note on Wednesday, February 26th.

Minerva Neurosciences Price Performance

NERV opened at $1.85 on Wednesday. Minerva Neurosciences has a 52 week low of $1.42 and a 52 week high of $3.69. The stock has a market cap of $12.94 million, a PE ratio of -4.20 and a beta of 0.10. The business has a 50 day moving average of $1.95 and a 200-day moving average of $2.25.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.49. Equities analysts anticipate that Minerva Neurosciences will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC lifted its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the quarter. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 34.56% of the stock is owned by hedge funds and other institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.